Using ultrasound and molecular testing to guide lymph node staging in endometrial cancer
Studies which women with endometrial cancer may not need lymph node staging.
Plain-language title generated from the registry record
Registry title: Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging
Key facts
- Where
- Hradec Králové, CzechiaSee the site
Where in Czechia
- University Hospital Hradec KraloveHradec Králové, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Hradec Kralove
- Trial code
- NCT07368205
- Record updated
- 22 May 2026
- Original description
The goal of this observational study is to evaluaty the accuracy of current risk stratification of patients with endometrial cancer and to redefine lymph node staging recommendations based on real-world clinical data. The main question it aims to answer is:Read full original descriptionShow less
Preoperative Risk Stratification in Endometrial Cancer Using Expert Ultrasound and Molecular Classification for Tailoring Lymph Node Staging: Multicentric Prospective Observational Study
The goal of this observational study is to evaluaty the accuracy of current risk stratification of patients with endometrial cancer and to redefine lymph node staging recommendations based on real-world clinical data. The main question it aims to answer is:
Is there any group of patients who doesn't need lymph node staging for proper indication of adjuvant treatment? Participants are note taking any intervention. They are treated according to current standard of care and followed 3-years after primary surgery.
Inclusion: Women ≥18 years with newly diagnosed endometrial cancer (any histology); Undergoing primary surgical management; Preoperative expert ultrasound, CT scan (could be waived in low risk cases); Preoperatively early-stage (stage I-II) of EC; SLN mapping attempted intraoperatively; FFPE tumor tissue available for molecular and IHC testing from biopsy; Signed informed consent with the participation in the study.
Exclusion: Prior oncological treatment within the last five years; Recurrent or metastatic disease at diagnosis; Cancer synchronous duplicity; Neoadjuvant treatment; Inadequate imaging or tissue samples.